

WEDNESDAY, 23rd MAY 2018 COMMENCING 09:30 AM
AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

- | | Enclosure |
|--------------------------------|--------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0518 |

To protect commercial confidentiality the following appraisals will be held in private

- | | |
|--|----------------------------|
| 5. Appraisal 1: Full Submission (PAS)
Ranibizumab (Lucentis®) for the treatment of visual impairment in adults due to choroidal neovascularisation not due to pathological myopia or wet age-related macular degeneration | 2/AWMSG/0518
Appendices |
| 6. Appraisal 2: Limited Submission (WPAS)
Icatibant acetate (Firazyr®) for the symptomatic treatment of acute attacks of hereditary angioedema in adolescents and children aged 2 years and older (with C1-esterase-inhibitor deficiency) | 3/AWMSG/0518
Appendices |
| 7. Appraisal 3: Full Submission (WPAS)
Selexipag (Uptravi®) for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. | 4/AWMSG/0518
Appendices |

The meeting will now open to the public

- | | |
|---|--------------|
| 8. Chairman's report (verbal update) | |
| 9. Common Ailments Service – Patient Information Leaflets | 5/AWMSG/0518 |
| 10. National Prescribing Indicators 2017-2018 Data to December 2017 | 6/AWMSG/0518 |

Date of next meeting – Wednesday, 20th June in Cardiff